Clinical Trial Update: Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating preoperative docetaxel for localized progressive castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN